Showing results (81-90 of 92) with videos related to
Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2024
Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor-Mutated Metastatic Non-Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722Tony Mok, Kazuhiko Nakagawa, Keunchil Park, et al.Cancer Discovery|April 11, 2022
Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion MutationsMengzhao Wang, James Chih-Hsin Yang, Paul L Mitchell, et al.Thoracic Cancer|January 18, 2023
Old age and EGFR mutation status in inoperable early-stage non-small cell lung cancer patients receiving stereotactic ablative radiotherapy: A single institute experience of 71 patients in TaiwanYuan-Hung Wu, Yu-Mei Kang, Yu-Wen Hu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 11, 2015
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I MutationsChao-Hua Chiu, Cheng-Ta Yang, Jin-Yuan Shih, et al.Oncotarget|May 19, 2016
Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking statusChia-Hung Hsu, Chien-Hua Tseng, Chun-Ju Chiang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2020
Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 TrialJames Chih-Hsin Yang, D Ross Camidge, Cheng-Ta Yang, et al.JTO Clinical and Research Reports|January 29, 2025
Durvalumab, Tremelimumab, and Platinum Chemotherapy in <i>EGFR</i> Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)Chee Khoon Lee, Bin-Chi Liao, Shalini Subramaniam, et al.The Lancet. Oncology|December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trialsAlexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 21, 2021
Efficacy of Aumolertinib (HS-10296) in Patients With Advanced EGFR T790M+ NSCLC: Updated Post-National Medical Products Administration Approval Results From the APOLLO Registrational TrialShun Lu, Qiming Wang, Guojun Zhang, et al.The Lancet. Respiratory Medicine|December 2, 2023
Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort studyGee-Chen Chang, Chao-Hua Chiu, Chong-Jen Yu, et al.Pageof 10